A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery
- PMID: 15609367
- DOI: 10.1002/rcm.1777
A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery
Abstract
A novel liquid chromatography/tandem mass spectrometry (LC/MS/MS)-based depletion method for measuring compound partitioning between human plasma and red blood cells (RBC) in a drug discovery environment is presented. Conventionally, RBC partitioning is determined by separate measurements of drug concentrations in equilibrating plasma and whole blood or RBC using separate standards prepared in their respective matrices, i.e., in plasma and whole blood or RBC lysates. The process is very tedious, labor-intensive, and difficult to automate. In addition, interferences from the heme and other highly abundant cellular composites make the measurement of the drug concentration in whole blood or RBC inevitably variable even with a highly specific LC/MS/MS method. Therefore, there is an imminent need to develop a straightforward and fast method to assess the partitioning of drug-like compounds in RBC. This work describes an LC/MS/MS-based depletion assay that measures the compound concentration in plasma that has been equilibrating with RBC. Compounds were spiked into fresh human whole blood and plasma respectively to a final concentration of 500 nM. Both the spiked whole blood and plasma control were incubated at 37 degrees C for up to 60 min. During the time course, aliquots of plasma and whole blood from both incubation mixtures were sampled at 10 and 60 min. The whole blood samples were centrifuged to yield the plasma. The plasma samples from both incubations were extracted using a protein precipitation method, and analyzed using LC/MS/MS under the multiple-reaction monitoring (MRM) mode. The RBC partitioning ratio was calculated using the analyte peak area responses of the plasma samples through an equation deduced in this work. The method was first tested using two commercial compounds, phenoprobamate and acetazolamide, to determine the optimal incubation conditions and the concentration dependency of the assay. The assay reproducibility was also assessed by three inter-day assays for phenoprobamate. This method was further evaluated using 20 commercial compounds of different classes with a wide range of RBC partitioning coefficients and the results were compared with those reported in the literature. Excellent correlation (R2=0.9396) was found between the measured and literature values. In addition, several proprietary compounds were assayed using both the new and traditional methods and the measured partitioning ratios from the two methods are equivalent. The experiments in this work demonstrate that the LC/MS/MS-based depletion method can provide direct and accurate measurement of RBC partitioning for compounds in drug discovery.
Similar articles
-
Measurement of total homocysteine in plasma and blood spots using liquid chromatography-tandem mass spectrometry: comparison with the plasma Abbott IMx method.Ann Clin Biochem. 2003 Mar;40(Pt 2):161-5. doi: 10.1258/000456303763046094. Ann Clin Biochem. 2003. PMID: 12662404
-
A liquid chromatography-mass spectrometry assay for simultaneous determination of two antimalarial thiazolium compounds in human and rat matrices.J Pharm Biomed Anal. 2008 Nov 4;48(3):1001-5. doi: 10.1016/j.jpba.2008.06.018. Epub 2008 Jul 5. J Pharm Biomed Anal. 2008. PMID: 18678456
-
A sample preparation process for LC-MS/MS analysis of total protein drug concentrations in monkey plasma samples with antibody.J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 1;847(2):133-41. doi: 10.1016/j.jchromb.2006.09.039. Epub 2006 Oct 18. J Chromatogr B Analyt Technol Biomed Life Sci. 2007. PMID: 17052964
-
The current role of liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressant and antiretroviral drugs.Clin Biochem. 2011 Jan;44(1):14-20. doi: 10.1016/j.clinbiochem.2010.06.012. Epub 2010 Jul 1. Clin Biochem. 2011. PMID: 20599871 Review.
-
Recent development in high-throughput bioanalytical support for in vitro ADMET profiling.Expert Opin Drug Metab Toxicol. 2010 Mar;6(3):321-36. doi: 10.1517/17425250903547829. Expert Opin Drug Metab Toxicol. 2010. PMID: 20163321 Review.
Cited by
-
Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies.Front Pharmacol. 2024 Jun 14;15:1392209. doi: 10.3389/fphar.2024.1392209. eCollection 2024. Front Pharmacol. 2024. PMID: 38948472 Free PMC article.
-
Facilitated uptake of a bioactive metabolite of maritime pine bark extract (pycnogenol) into human erythrocytes.PLoS One. 2013 Apr 30;8(4):e63197. doi: 10.1371/journal.pone.0063197. Print 2013. PLoS One. 2013. PMID: 23646194 Free PMC article.
-
Analysis of Time-Dependent Pharmacokinetics Using In Vitro-In Vivo Extrapolation and Physiologically Based Pharmacokinetic Modeling.Pharmaceutics. 2022 Nov 22;14(12):2562. doi: 10.3390/pharmaceutics14122562. Pharmaceutics. 2022. PMID: 36559055 Free PMC article.
-
The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study.Drug Metab Dispos. 2022 Feb;50(2):158-167. doi: 10.1124/dmd.121.000640. Epub 2021 Nov 10. Drug Metab Dispos. 2022. PMID: 34759012 Free PMC article.
-
Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo Findings.Molecules. 2022 Jan 6;27(2):339. doi: 10.3390/molecules27020339. Molecules. 2022. PMID: 35056659 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources